Literature DB >> 21865401

MRI apparent diffusion coefficient reflects histopathologic subtype, axonal disruption, and tumor fraction in diffuse-type grade II gliomas.

Inas S Khayal1, Scott R Vandenberg, Kenneth J Smith, Colleen P Cloyd, Susan M Chang, Soonmee Cha, Sarah J Nelson, Tracy R McKnight.   

Abstract

The apparent diffusion coefficient (ADC) determined from MR diffusion tensor imaging (DTI) has shown promise for distinguishing World Health Organization grade II astrocytoma (AS) from the more prognostically favorable grade II oligodendroglioma (OD). Since mixed oligoastrocytomas (OAs) with codeletions in chromosomes 1p and 19q confer prognoses similar to those of OD, we questioned whether a previously determined ADC-based criterion for distinguishing OD and AS would hold on an independent set of gliomas that included OA with codeleted or intact 1p/19q chromosomes. We also questioned whether the ADC is associated with the tumor microstructure. ADC colormaps generated from presurgical DTI scans were used to guide the collection of biopsies from each tumor. The median normalized ADC distinguished OD from AS with 91% sensitivity and 92% specificity. 1p/19q codeleted OAs were always classified as ODs, while 1p/19q intact OAs were always classified as ASs. There were positive associations between the ADC and both the SMI-31 score of axonal disruption and the fraction of tumor cells in the biopsies. The ADC of OD and 1p/19q codeleted OA was more associated with tumor fraction, while the ADC of AS and 1p/19q intact OA was more associated with SMI-31 score. We conclude that our previously determined threshold median ADC can distinguish grade II OD and AS on a new patient cohort and that the distinctions extend to OA with codeleted and intact 1p/19q chromosomes. Further, the ADC in grade II gliomas is associated with the fraction of tumor cells and degree of axonal disruption in tumor subregions.

Entities:  

Mesh:

Year:  2011        PMID: 21865401      PMCID: PMC3199150          DOI: 10.1093/neuonc/nor122

Source DB:  PubMed          Journal:  Neuro Oncol        ISSN: 1522-8517            Impact factor:   12.300


  29 in total

1.  Segmentation of brain MR images through a hidden Markov random field model and the expectation-maximization algorithm.

Authors:  Y Zhang; M Brady; S Smith
Journal:  IEEE Trans Med Imaging       Date:  2001-01       Impact factor: 10.048

2.  Histopathological-molecular genetic correlations in referral pathologist-diagnosed low-grade "oligodendroglioma".

Authors:  Hikaru Sasaki; Magdalena C Zlatescu; Rebecca A Betensky; Loki B Johnk; Andrea N Cutone; J Gregory Cairncross; David N Louis
Journal:  J Neuropathol Exp Neurol       Date:  2002-01       Impact factor: 3.685

3.  Relationships between choline magnetic resonance spectroscopy, apparent diffusion coefficient and quantitative histopathology in human glioma.

Authors:  R K Gupta; T F Cloughesy; U Sinha; J Garakian; J Lazareff; G Rubino; L Rubino; D P Becker; H V Vinters; J R Alger
Journal:  J Neurooncol       Date:  2000-12       Impact factor: 4.130

4.  PCV for oligodendroglial tumors: in search of prognostic factors for response and survival.

Authors:  D Fortin; D R Macdonald; L Stitt; J G Cairncross
Journal:  Can J Neurol Sci       Date:  2001-08       Impact factor: 2.104

5.  Imaging correlates of molecular signatures in oligodendrogliomas.

Authors:  Joseph F Megyesi; Edward Kachur; Donald H Lee; Magdalena C Zlatescu; Rebecca A Betensky; Peter A Forsyth; Yoshifumi Okada; Hikaru Sasaki; Masahiro Mizoguchi; David N Louis; J Gregory Cairncross
Journal:  Clin Cancer Res       Date:  2004-07-01       Impact factor: 12.531

6.  Population-based study on incidence, survival rates, and genetic alterations of low-grade diffuse astrocytomas and oligodendrogliomas.

Authors:  Yoshikazu Okamoto; Pier-Luigi Di Patre; Christoph Burkhard; Sonja Horstmann; Benjamin Jourde; Michael Fahey; Danielle Schüler; Nicole M Probst-Hensch; M Gazi Yasargil; Yasuhiro Yonekawa; Urs M Lütolf; Paul Kleihues; Hiroko Ohgaki
Journal:  Acta Neuropathol       Date:  2004-04-28       Impact factor: 17.088

7.  Coregistration accuracy and detection of brain shift using intraoperative sononavigation during resection of hemispheric tumors.

Authors:  G Evren Keles; Kathleen R Lamborn; Mitchel S Berger
Journal:  Neurosurgery       Date:  2003-09       Impact factor: 4.654

8.  Selective expression of a subset of neuronal genes in oligodendroglioma with chromosome 1p loss.

Authors:  Akitake Mukasa; Keisuke Ueki; Xijin Ge; Shumpei Ishikawa; Takafumi Ide; Takamitsu Fujimaki; Ryo Nishikawa; Akio Asai; Takaaki Kirino; Hiroyuki Aburatani
Journal:  Brain Pathol       Date:  2004-01       Impact factor: 6.508

Review 9.  New perspectives for the diagnosis and treatment of oligodendroglioma.

Authors:  M J van den Bent
Journal:  Expert Rev Anticancer Ther       Date:  2001-10       Impact factor: 4.512

Review 10.  Genetic alterations and chemotherapeutic response in human diffuse gliomas.

Authors:  G J Kitange; J S Smith; R B Jenkins
Journal:  Expert Rev Anticancer Ther       Date:  2001-12       Impact factor: 4.512

View more
  15 in total

1.  Combined diffusion and perfusion MR imaging as biomarkers of prognosis in immunocompetent patients with primary central nervous system lymphoma.

Authors:  F E Valles; C L Perez-Valles; S Regalado; R F Barajas; J L Rubenstein; S Cha
Journal:  AJNR Am J Neuroradiol       Date:  2012-08-30       Impact factor: 3.825

Review 2.  Genetics and imaging of oligodendroglial tumors.

Authors:  Jonathan R Ellenbogen; Carol Walker; Michael D Jenkinson
Journal:  CNS Oncol       Date:  2015-10-19

3.  Tumor hypoxia and microscopic diffusion capacity in brain tumors: a comparison of (62)Cu-Diacetyl-Bis (N4-Methylthiosemicarbazone) PET/CT and diffusion-weighted MR imaging.

Authors:  Ayako Hino-Shishikura; Ukihide Tateishi; Hirofumi Shibata; Tomohiro Yoneyama; Toshiaki Nishii; Ikuo Torii; Kensuke Tateishi; Makoto Ohtake; Nobutaka Kawahara; Tomio Inoue
Journal:  Eur J Nucl Med Mol Imaging       Date:  2014-04-10       Impact factor: 9.236

4.  Regional variation in histopathologic features of tumor specimens from treatment-naive glioblastoma correlates with anatomic and physiologic MR Imaging.

Authors:  Ramon F Barajas; Joanna J Phillips; Rupa Parvataneni; Annette Molinaro; Emma Essock-Burns; Gabriela Bourne; Andrew T Parsa; Manish K Aghi; Michael W McDermott; Mitchel S Berger; Soonmee Cha; Susan M Chang; Sarah J Nelson
Journal:  Neuro Oncol       Date:  2012-06-18       Impact factor: 12.300

5.  Quantitative multi-modal MR imaging as a non-invasive prognostic tool for patients with recurrent low-grade glioma.

Authors:  Evan Neill; Tracy Luks; Manisha Dayal; Joanna J Phillips; Arie Perry; Llewellyn E Jalbert; Soonmee Cha; Annette Molinaro; Susan M Chang; Sarah J Nelson
Journal:  J Neurooncol       Date:  2017-01-25       Impact factor: 4.130

6.  Noninvasive Assessment of IDH Mutational Status in World Health Organization Grade II and III Astrocytomas Using DWI and DSC-PWI Combined with Conventional MR Imaging.

Authors:  Z Xing; X Yang; D She; Y Lin; Y Zhang; D Cao
Journal:  AJNR Am J Neuroradiol       Date:  2017-04-27       Impact factor: 3.825

7.  Hypovascular Cellular Tumor in Primary Central Nervous System Lymphoma is Associated with Treatment Resistance: Tumor Habitat Analysis Using Physiologic MRI.

Authors:  S Y Jeong; J E Park; N Kim; H S Kim
Journal:  AJNR Am J Neuroradiol       Date:  2021-11-25       Impact factor: 3.825

8.  Can diffusion tensor imaging noninvasively detect IDH1 gene mutations in astrogliomas? A retrospective study of 112 cases.

Authors:  W L Tan; W Y Huang; B Yin; J Xiong; J S Wu; D Y Geng
Journal:  AJNR Am J Neuroradiol       Date:  2014-02-20       Impact factor: 3.825

9.  Lower apparent diffusion coefficients indicate distinct prognosis in low-grade and high-grade glioma.

Authors:  Yong Cui; Li Ma; Xuzhu Chen; Zhe Zhang; Haihui Jiang; Song Lin
Journal:  J Neurooncol       Date:  2014-05-30       Impact factor: 4.130

10.  Apparent diffusion coefficient in glioblastoma with PNET-like components, a GBM variant.

Authors:  Saad Ali; Nancy M Joseph; Arie Perry; Ramon F Barajas; Soonmee Cha
Journal:  J Neurooncol       Date:  2014-06-04       Impact factor: 4.130

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.